Oskar Axelsson

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Top Venues

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Sujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
177 Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model. Investigational new drugs 42 (4) (2024)
Sujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
177 Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model. Investigational new drugs 42 (4) (2024)
Sujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
177 Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model. Investigational new drugs 42 (4) (2024)
Sujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
177 Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model. Investigational new drugs (2024)
Ingrid Yao Mattisson, Sania Bäckström, Erik Ekengard, Sujinna Lekmeechai, Yi-Chi Liu, Juraj Paris, Rodrigo Petoral, Marie Sydoff, Mats Hansen, Oskar Axelsson
Characterization and Efficacy of a Nanomedical Radiopharmaceutical for Cancer Treatment. ACS omega 8 (2) (2023)
Ingrid Yao Mattisson, Sania Bäckström, Erik Ekengard, Sujinna Lekmeechai, Yi-Chi Liu, Juraj Paris, Rodrigo Petoral, Marie Sydoff, Mats Hansen, Oskar Axelsson
Characterization and Efficacy of a Nanomedical Radiopharmaceutical for Cancer Treatment. ACS omega 8 (2) (2023)